Faron Pharmaceuticals Oy (LON:FARN – Get Free Report)’s stock price passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of GBX 184.50 and traded as low as GBX 164.50. Faron Pharmaceuticals Oy shares last traded at GBX 167.98, with a volume of 11,924 shares trading hands.
Faron Pharmaceuticals Oy Trading Up 1.8%
The company has a debt-to-equity ratio of 922.55, a current ratio of 1.45 and a quick ratio of 1.09. The firm has a market cap of £191.33 million, a price-to-earnings ratio of -6.22 and a beta of 0.36. The firm’s fifty day moving average is GBX 184.50 and its 200-day moving average is GBX 196.66.
Faron Pharmaceuticals Oy Company Profile
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
See Also
- Five stocks we like better than Faron Pharmaceuticals Oy
- What is a penny stock? A comprehensive guide
- Nike Beats on Earnings But Struggles in China and Faces Tariffs
- What is the Euro STOXX 50 Index?
- Is the AI Boom a Bubble? These 2 Dividend Stocks Say No
- Conference Calls and Individual Investors
- 4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
